Septerna, Inc. AI Stock Analysis
Want to see SEPN full AI Analyst Report?
Septerna, Inc. (SEPN) AI Stock Analysis
Septerna, Inc.
(NASDAQ:SEPN)
The score is held back primarily by weak and volatile financial performance (losses, sharp revenue swing, and current cash burn) despite a strong, low-leverage balance sheet. Offsetting this, technicals show solid bullish momentum with price above major moving averages and a positive MACD. Valuation is constrained by negative earnings and no dividend support, while recent corporate events add a modest positive pipeline/execution signal.
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.31B
- Dividend Yield
- ―
- Average Volume (3M)
- 397.70K
- Price to Earnings (P/E)
- -37.6
- Beta (1Y)
- 1.88
- Revenue Growth
- 336.69%
- EPS Growth
- 14.29%
- Country
- US
- Employees
- 130
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R P...
Septerna, Inc. Financial Statement Overview
Summary
Financials are mixed and risk-tilted: the balance sheet is a key strength (low leverage with ~$22.0M debt vs ~$427.9M equity), but operating performance is weak with a TTM net loss of ~$59.0M, sharply volatile revenue (reported growth -264%), and meaningful cash burn (TTM operating cash flow -$76.6M; free cash flow -$77.6M).
Income Statement
36NegativeBalance Sheet
74PositiveCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 96.27M | 45.95M | 1.07M | 151.00K | 0 |
| Gross Profit | 76.97M | 45.95M | 1.07M | 151.00K | 0 |
| EBITDA | -57.07M | -47.26M | -70.89M | -44.70M | -27.39M |
| Net Income | -59.00M | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | |||||
| Total Assets | 619.40M | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 478.60M | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 21.99M | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 191.47M | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 427.93M | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | |||||
| Free Cash Flow | -77.59M | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | -76.57M | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -157.22M | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 80.93M | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Positive. The current price of 48.56 is above the 20-day moving average (MA) of 43.66, above the 50-day MA of 40.26, and above the 200-day MA of 32.94, indicating a bullish trend. The MACD of 2.98 indicates Negative momentum. The RSI at 63.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskSepterna, Inc. Peers Comparison
Overall Rating
- SEPN56Neutral
BHVN52Neutral
RAPP51Neutral
PHVS46Neutral
GPCR42Neutral
GHRS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SEPN | 56Neutral | $2.49B | -37.64 | -14.98% | ― | 336.69% | 14.29% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| BHVN | 52Neutral | $2.28B | -3.94 | -2271.87% | ― | ― | 49.16% |
| RAPP | 51Neutral | $1.54B | -8.52 | -34.00% | ― | ― | -17.88% |
| PHVS | 46Neutral | $2.39B | -11.41 | -61.24% | ― | ― | 9.42% |
| GPCR | 42Neutral | $1.55B | -5.37 | -21.24% | ― | ― | -8.08% |
| GHRS | 39Underperform | $1.34B | -19.25 | -20.86% | ― | ― | -33.76% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | 48.56 | 25.30 | 108.77% | |
| PHVS | Pharvaris N.V. | 34.18 | 10.63 | 45.14% | |
| GHRS | Gh Research Plc | 19.25 | 5.25 | 37.50% | |
| BHVN | Biohaven Ltd. | 15.19 | 6.89 | 83.01% | |
| GPCR | Structure Therapeutics, Inc. Sponsored ADR | 20.95 | -15.87 | -43.10% | |
| RAPP | Rapport Therapeutics, Inc. | 27.02 | 2.65 | 10.87% |
Septerna, Inc. Corporate Events
Septerna Selects SEP-204 Candidate for Graves’ Disease
PositiveSepterna is a clinical-stage biotechnology company advancing oral small-molecule GPCR drug candidates through its Native Complex Platform, with programs spanning endocrinology, immunology and inflammation, metabolic diseases and other areas. On Novem...
Septerna Appoints Rajiv Patni as Chief Medical Officer
PositiveSepterna, Inc., a clinical-stage biotechnology company specializing in GPCR-targeted oral small-molecule therapies for unmet needs in endocrinology, immunology, inflammation and metabolic diseases, is building a diversified pipeline enabled by its Na...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026